GlassScriptPhysician profile
Kate C Browne
NPI 1942956735
$1,421.08
in general payments reported to CMS, 2019-2025
22 companies · $597 in 2025
The $597 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $305 · 2024: $400 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.69 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $322.15 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $194.73 | 2023-2025 | Clonoseq |
| Celgene Corporation | $128.71 | 2022-2025 | Pomalyst, Reblozyl |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Abbvie INC. | $93.20 | 2024-2025 | |
| Incyte Corporation | $92.99 | 2025 | |
| Beigene USA, INC. | $84.07 | 2023-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $67.91 | 2025 | Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.61 | 2025 | |
| Servier Pharmaceuticals LLC | $38.20 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $28.72 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $28.68 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $23.75 | 2023 | Lynparza, Keytruda |
| Deciphera Pharmaceuticals INC. | $22.71 | 2024 | Qinlock |
| Pfizer INC. | $21.67 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.36 | 2024 | Ojjaara |
| Puma Biotechnology, INC. | $21.01 | 2024 | |
| Immunocore Limited | $20.29 | 2025 | Kimmtrak |
| Pharmacosmos Therapeutics INC. | $18.19 | 2024 | Cosela |
| Amgen INC. | $15.41 | 2023 | Xgeva |
| Genzyme Corporation | $14.47 | 2023 | |
| Dendreon Pharmaceuticals LLC | $13.26 | 2024 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.